These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 15478634)

  • 21. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.
    Wood MD; Wren PB
    Prog Brain Res; 2008; 172():213-30. PubMed ID: 18772035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension.
    Wang HL
    Curr Opin Investig Drugs; 2004 Sep; 5(9):963-6. PubMed ID: 15503652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence.
    Szilagyi A; Boór K; Székely A; Gaszner P; Kalász H; Sasvári-Székely M; Barta C
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):28-33. PubMed ID: 16167465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
    Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
    Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic drug action: targets for drug discovery with neurochemical imaging.
    Stone JM; Pilowsky LS
    Expert Rev Neurother; 2006 Jan; 6(1):57-64. PubMed ID: 16466312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.
    Kim JY; Jung IK; Han C; Cho SH; Kim L; Kim SH; Lee BH; Lee HJ; Kim YK
    Psychiatry Clin Neurosci; 2005 Apr; 59(2):183-8. PubMed ID: 15823165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent.
    Plisson C; Stehouwer JS; Voll RJ; Howell L; Votaw JR; Owens MJ; Goodman MM
    J Med Chem; 2007 Sep; 50(19):4553-60. PubMed ID: 17705359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
    Paris I; Martinez-Alvarado P; Perez-Pastene C; Vieira MN; Olea-Azar C; Raisman-Vozari R; Cardenas S; Graumann R; Caviedes P; Segura-Aguilar J
    J Neurochem; 2005 Mar; 92(5):1021-32. PubMed ID: 15715653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinylogous amide analogs of methylphenidate.
    Froimowitz M; Gu Y; Dakin LA; Kelley CJ; Parrish D; Deschamps JR
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3044-7. PubMed ID: 15908207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Problems on FDA phase IV drug evaluation of antipsychotic agents].
    Kazematsuri G
    Seishin Shinkeigaku Zasshi; 1990; 92(9):592-6. PubMed ID: 1980370
    [No Abstract]   [Full Text] [Related]  

  • 32. [Optimization criteria for antipsychotic therapy: therapeutic margin].
    Martínez Granados F; Pol Yangüas E
    Farm Hosp; 2004; 28(3):214-24. PubMed ID: 15222876
    [No Abstract]   [Full Text] [Related]  

  • 33. Personalized drug therapy with pharmacogenetics--part 2: pharmacodynamics.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2006 Feb; 44(2):13-6. PubMed ID: 16526527
    [No Abstract]   [Full Text] [Related]  

  • 34. New antipsychotic agents are much awaited.
    Chakraborti A
    BMJ; 2006 Jun; 332(7556):1511. PubMed ID: 16793829
    [No Abstract]   [Full Text] [Related]  

  • 35. Imaging neurochemical endophenotypes: promises and pitfalls.
    Martinez D; Broft A; Laruelle M
    Pharmacogenomics; 2001 Aug; 2(3):223-37. PubMed ID: 11535111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the use of positron emission tomography for neuroreceptor imaging in rabbit eyes.
    Wang WF; Ishiwata K; Kiyosawa M; Kawamura K; Oda K; Matsuno K; Kobayashi T; Mochizuki M
    Ophthalmic Res; 2004; 36(5):255-63. PubMed ID: 15583431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Usefulness of PET in clinical trials of psychotropic drugs].
    Suhara T; Morimoto T
    Seishin Shinkeigaku Zasshi; 2005; 107(7):704-11. PubMed ID: 16250122
    [No Abstract]   [Full Text] [Related]  

  • 38. [Stimulants related mental disorders].
    Iyo M; Sekine Y
    Ryoikibetsu Shokogun Shirizu; 2003; (40):507-12. PubMed ID: 14626172
    [No Abstract]   [Full Text] [Related]  

  • 39. [Evaluation of drug therapy based on the results of imaging].
    Suhara T
    Seishin Shinkeigaku Zasshi; 2004; 106(7):916-20. PubMed ID: 15478634
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.